Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4156956 | 1.00 | S1PR1 (0.56) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL13875328 | 0.89 | S1PR1 (0.58) | S1PR1ADAMTS5MMP2UTS2R | |
| SCHEMBL4159021 | 0.87 | S1PR1 (0.56) | S1PR1ADAMTS5MMP2UTS2R | |
| SCHEMBL4384846 | 0.86 | S1PR1 (0.59) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4168401 | 0.86 | S1PR1 (0.59) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4169110 | 0.85 | S1PR1 (0.53) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL4166457 | 0.83 | S1PR1 (0.52) | S1PR1ADAMTS5MMP2UTS2RCA2 | |
| SCHEMBL4164065 | 0.79 | S1PR1 (0.60) | S1PR1MMP2CA2 | |
| SCHEMBL4165496 | 0.78 | S1PR1 (0.52) | S1PR1ADAMTS5MMP2 | |
| SCHEMBL4363505 | 0.78 | S1PR1 (0.58) | S1PR1ADAMTS5MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013184-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007129019-A1 | SULFONAMIDE COMPOUNDS USEFUL AS EDG RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |